Management rebuilt the commercial organization in 2025, grew the salesforce to just over 90 and plans to expand to approximately 120 in 2026 while investing in technology—moves management says are ...
Hosted on MSN
Biote reiterates 2025 revenue guidance above $190M as commercial team rebuild progresses
Peterson stated, "we reiterate our fiscal 2025 revenue guidance of above $190 million and our fiscal 2025 adjusted EBITDA guidance of above $50 million." Management continues to expect mid-teens ...
Represents cash and non-cash interest on our debt obligations, commitment fees for our unused Revolving Loans, net of interest income earned on our money market account. Interest expense, net, ...
Biote (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners’ patients, today announced financial results for the ...
View biote Corp. Class A BTMD stock quote prices, financial information, real-time forecasts, and company news from CNN.
IRVING, Texas--(BUSINESS WIRE)--biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization ...
Represents an inventory impairment charge of $1.3 million related to the January 2026 voluntary recall of select lots of bioidentical hormone pellets shipped by Asteria Health between May 2025 and ...
biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our Practitioners’ patients, today ...
biote Corp. (BTMD) came out with quarterly earnings of $0.06 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.08 per share a year ago. These figures ...
Irving-based hormone therapy firm Biote Corp. will buy back nearly $77 million in stock to settle a lawsuit filed by the company's founder. The money will go to Gary Donovitz, who founded the company ...
Biote maintains 2026 outlook above $190M revenue as it targets restoring Asteria supply by end of Q2
CEO Bret Christensen said the quarter was shaped by the company’s operational work on clinic growth and support, but also by a voluntary recall-related disruption: “Over the past 12 months, we have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results